Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan

Evaluation by rapid turnover proteins, and radiologic and endoscopic findings

Hitoshi Asakura, Tsuneyoshi Yao, Toshiyuki Matsui, Kazutaka Koganei, Tsuneo Fukushima, Masakazu Takazoe, Reiko Hobara, Hiroshi Nakano, Shouzou Okamura, Kei Matsueda, Hiroshi Kashida, Kazuya Makiyama, Nobuo Hiwatashi, Kazuhiro Kashiwagi, Toshifumi Hibi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Several studies have reported that the chimeric monoclonal antibody to tumor necrosis factor (TNF)-α (Infliximab) is extremely valuable in the treatment of Crohn's disease. The aim of this study was to clarify the efficacy of this treatment in Japanese patients with Crohn's disease. Methods: A 12-week multicenter, open trial of Infliximab was carried out and involved 25 patients with moderate to severe Crohn's disease who were resistant to conventional treatment. Patients received a single 2-h intravenous infusion of Infliximab at a dose of 1, 3, 5 or 10 mg/kg bodyweight. Clinical evaluation of this treatment response was defined as a reduction in the index of the inflammatory bowel disease (IOIBD) and of the Crohn's disease activity index scores (CDAI), and in serum levels of C-reactive protein (CRP) at 2, 4, 8 and 12 weeks, and as an increase in serum levels of rapid turnover proteins as well as improvement of radiologic and endoscopic findings at 4 weeks. Results: The IOIBD score was reduced after 4 weeks in 66.7% of the group receiving 1 mg/kg Infliximab, 71.4% in the group receiving 3 mg/kg, 80.0% in the group receiving 5 mg/kg, and 85.7% in the group receiving 10 mg/kg. Improvement was better maintained over 12 weeks in the 5 and 10 mg/kg groups compared with the 1 and 3 mg/kg groups. Similar results were obtained for the CDAI scores. Serum levels of rapid turnover proteins significantly increased to within the normal ranges after infusion in all groups. Seven of the 11 (63.6%) patients evaluated showed improvement of radiologic and endoscopic findings. Conclusions: A single infusion of Infliximab was effective for the treatment of Japanese patients with Crohn's disease. Serum rapid turnover proteins reflected the clinical response to antibody for TNF-α well.

Original languageEnglish
Pages (from-to)763-769
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume16
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

Crohn Disease
Japan
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Proteins
Serum
Inflammatory Bowel Diseases
compound A 12
Therapeutics
Intravenous Infusions
C-Reactive Protein
Multicenter Studies
Antibody Formation
Infliximab
Reference Values

Keywords

  • Crohn's disease
  • Crohn's disease activity index
  • Index of inflammatory bowel disease
  • Monoclonal antibody
  • Rapid turnover proteins
  • Treatment
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan : Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. / Asakura, Hitoshi; Yao, Tsuneyoshi; Matsui, Toshiyuki; Koganei, Kazutaka; Fukushima, Tsuneo; Takazoe, Masakazu; Hobara, Reiko; Nakano, Hiroshi; Okamura, Shouzou; Matsueda, Kei; Kashida, Hiroshi; Makiyama, Kazuya; Hiwatashi, Nobuo; Kashiwagi, Kazuhiro; Hibi, Toshifumi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 16, No. 7, 2001, p. 763-769.

Research output: Contribution to journalArticle

Asakura, H, Yao, T, Matsui, T, Koganei, K, Fukushima, T, Takazoe, M, Hobara, R, Nakano, H, Okamura, S, Matsueda, K, Kashida, H, Makiyama, K, Hiwatashi, N, Kashiwagi, K & Hibi, T 2001, 'Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings', Journal of Gastroenterology and Hepatology (Australia), vol. 16, no. 7, pp. 763-769. https://doi.org/10.1046/j.1440-1746.2001.02507.x
Asakura, Hitoshi ; Yao, Tsuneyoshi ; Matsui, Toshiyuki ; Koganei, Kazutaka ; Fukushima, Tsuneo ; Takazoe, Masakazu ; Hobara, Reiko ; Nakano, Hiroshi ; Okamura, Shouzou ; Matsueda, Kei ; Kashida, Hiroshi ; Makiyama, Kazuya ; Hiwatashi, Nobuo ; Kashiwagi, Kazuhiro ; Hibi, Toshifumi. / Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan : Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. In: Journal of Gastroenterology and Hepatology (Australia). 2001 ; Vol. 16, No. 7. pp. 763-769.
@article{071d9b66b2294b4d87b7f292c34f4b8a,
title = "Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings",
abstract = "Background: Several studies have reported that the chimeric monoclonal antibody to tumor necrosis factor (TNF)-α (Infliximab) is extremely valuable in the treatment of Crohn's disease. The aim of this study was to clarify the efficacy of this treatment in Japanese patients with Crohn's disease. Methods: A 12-week multicenter, open trial of Infliximab was carried out and involved 25 patients with moderate to severe Crohn's disease who were resistant to conventional treatment. Patients received a single 2-h intravenous infusion of Infliximab at a dose of 1, 3, 5 or 10 mg/kg bodyweight. Clinical evaluation of this treatment response was defined as a reduction in the index of the inflammatory bowel disease (IOIBD) and of the Crohn's disease activity index scores (CDAI), and in serum levels of C-reactive protein (CRP) at 2, 4, 8 and 12 weeks, and as an increase in serum levels of rapid turnover proteins as well as improvement of radiologic and endoscopic findings at 4 weeks. Results: The IOIBD score was reduced after 4 weeks in 66.7{\%} of the group receiving 1 mg/kg Infliximab, 71.4{\%} in the group receiving 3 mg/kg, 80.0{\%} in the group receiving 5 mg/kg, and 85.7{\%} in the group receiving 10 mg/kg. Improvement was better maintained over 12 weeks in the 5 and 10 mg/kg groups compared with the 1 and 3 mg/kg groups. Similar results were obtained for the CDAI scores. Serum levels of rapid turnover proteins significantly increased to within the normal ranges after infusion in all groups. Seven of the 11 (63.6{\%}) patients evaluated showed improvement of radiologic and endoscopic findings. Conclusions: A single infusion of Infliximab was effective for the treatment of Japanese patients with Crohn's disease. Serum rapid turnover proteins reflected the clinical response to antibody for TNF-α well.",
keywords = "Crohn's disease, Crohn's disease activity index, Index of inflammatory bowel disease, Monoclonal antibody, Rapid turnover proteins, Treatment, Tumor necrosis factor-α",
author = "Hitoshi Asakura and Tsuneyoshi Yao and Toshiyuki Matsui and Kazutaka Koganei and Tsuneo Fukushima and Masakazu Takazoe and Reiko Hobara and Hiroshi Nakano and Shouzou Okamura and Kei Matsueda and Hiroshi Kashida and Kazuya Makiyama and Nobuo Hiwatashi and Kazuhiro Kashiwagi and Toshifumi Hibi",
year = "2001",
doi = "10.1046/j.1440-1746.2001.02507.x",
language = "English",
volume = "16",
pages = "763--769",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan

T2 - Evaluation by rapid turnover proteins, and radiologic and endoscopic findings

AU - Asakura, Hitoshi

AU - Yao, Tsuneyoshi

AU - Matsui, Toshiyuki

AU - Koganei, Kazutaka

AU - Fukushima, Tsuneo

AU - Takazoe, Masakazu

AU - Hobara, Reiko

AU - Nakano, Hiroshi

AU - Okamura, Shouzou

AU - Matsueda, Kei

AU - Kashida, Hiroshi

AU - Makiyama, Kazuya

AU - Hiwatashi, Nobuo

AU - Kashiwagi, Kazuhiro

AU - Hibi, Toshifumi

PY - 2001

Y1 - 2001

N2 - Background: Several studies have reported that the chimeric monoclonal antibody to tumor necrosis factor (TNF)-α (Infliximab) is extremely valuable in the treatment of Crohn's disease. The aim of this study was to clarify the efficacy of this treatment in Japanese patients with Crohn's disease. Methods: A 12-week multicenter, open trial of Infliximab was carried out and involved 25 patients with moderate to severe Crohn's disease who were resistant to conventional treatment. Patients received a single 2-h intravenous infusion of Infliximab at a dose of 1, 3, 5 or 10 mg/kg bodyweight. Clinical evaluation of this treatment response was defined as a reduction in the index of the inflammatory bowel disease (IOIBD) and of the Crohn's disease activity index scores (CDAI), and in serum levels of C-reactive protein (CRP) at 2, 4, 8 and 12 weeks, and as an increase in serum levels of rapid turnover proteins as well as improvement of radiologic and endoscopic findings at 4 weeks. Results: The IOIBD score was reduced after 4 weeks in 66.7% of the group receiving 1 mg/kg Infliximab, 71.4% in the group receiving 3 mg/kg, 80.0% in the group receiving 5 mg/kg, and 85.7% in the group receiving 10 mg/kg. Improvement was better maintained over 12 weeks in the 5 and 10 mg/kg groups compared with the 1 and 3 mg/kg groups. Similar results were obtained for the CDAI scores. Serum levels of rapid turnover proteins significantly increased to within the normal ranges after infusion in all groups. Seven of the 11 (63.6%) patients evaluated showed improvement of radiologic and endoscopic findings. Conclusions: A single infusion of Infliximab was effective for the treatment of Japanese patients with Crohn's disease. Serum rapid turnover proteins reflected the clinical response to antibody for TNF-α well.

AB - Background: Several studies have reported that the chimeric monoclonal antibody to tumor necrosis factor (TNF)-α (Infliximab) is extremely valuable in the treatment of Crohn's disease. The aim of this study was to clarify the efficacy of this treatment in Japanese patients with Crohn's disease. Methods: A 12-week multicenter, open trial of Infliximab was carried out and involved 25 patients with moderate to severe Crohn's disease who were resistant to conventional treatment. Patients received a single 2-h intravenous infusion of Infliximab at a dose of 1, 3, 5 or 10 mg/kg bodyweight. Clinical evaluation of this treatment response was defined as a reduction in the index of the inflammatory bowel disease (IOIBD) and of the Crohn's disease activity index scores (CDAI), and in serum levels of C-reactive protein (CRP) at 2, 4, 8 and 12 weeks, and as an increase in serum levels of rapid turnover proteins as well as improvement of radiologic and endoscopic findings at 4 weeks. Results: The IOIBD score was reduced after 4 weeks in 66.7% of the group receiving 1 mg/kg Infliximab, 71.4% in the group receiving 3 mg/kg, 80.0% in the group receiving 5 mg/kg, and 85.7% in the group receiving 10 mg/kg. Improvement was better maintained over 12 weeks in the 5 and 10 mg/kg groups compared with the 1 and 3 mg/kg groups. Similar results were obtained for the CDAI scores. Serum levels of rapid turnover proteins significantly increased to within the normal ranges after infusion in all groups. Seven of the 11 (63.6%) patients evaluated showed improvement of radiologic and endoscopic findings. Conclusions: A single infusion of Infliximab was effective for the treatment of Japanese patients with Crohn's disease. Serum rapid turnover proteins reflected the clinical response to antibody for TNF-α well.

KW - Crohn's disease

KW - Crohn's disease activity index

KW - Index of inflammatory bowel disease

KW - Monoclonal antibody

KW - Rapid turnover proteins

KW - Treatment

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=18144450891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144450891&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1746.2001.02507.x

DO - 10.1046/j.1440-1746.2001.02507.x

M3 - Article

VL - 16

SP - 763

EP - 769

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 7

ER -